No one should be on a particular medication or drug for life. The 10-year study reveals Diabetes Control and Complications Trial, DCCT and followed up Epidemiology of Diabetic Interventions and Complications, EDIC notice that people with type 1 diabetes can control the blood sugar levels within normal or near the normal range (tightly controlled therapy), and fewer incidence of eye, kidney or nerve damage from diabetes than standard therapy.
Signs of low blood sugar: Cold sweat; cool pale skin; headache; rapid heartbeat; feeling sick; feeling very hungry; temporary changes in vision; side effects of insulin shots drowsiness; unusual tiredness and weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in concentrating.
Dr Victoria King, from Diabetes UK, said: "This research, undertaken in isolated tissue from people without diabetes, indicates that C-peptide could also play a role in protecting against some of the cardiovascular related complications of diabetes but further investigation is needed to confirm this and before it can be shown that giving C-peptide treatment to people with diabetes can help protect them from some of the diabetes related cardiovascular risk associated with diabetes.
While the use of statins and diabetes does help, the FDA has warned that statin use may raise a patient's risk of developing diabetes type 2. This puts people in a quandary because so many patients with heart disease and high LDL cholesterol need statins to lower LDL cholesterol.
In the UK Prospective Diabetes Study (UKPDS) insulin treatment arm, HbA1c rose progressively during the 10 years of follow-up from ~6.3 to 8.0% ( 9 ). The percentage of insulin-treated patients who maintained an HbA1c <7% was 47% at 3 years, 37% at 6 years, and 28% at 9 years and was not different from individuals treated with sulfonylureas ( 10 ). More recent studies such as the 3-year Treating To Target in Type 2 Diabetes (4-T) study, which added insulin therapy to patients inadequately controlled on oral therapies, were able to achieve and maintain HbA1c at ~7% by combining multiple different insulin strategies and progressively increasing the daily doses of insulin administered ( 11 ). The consequences, as noted in the section on complications of therapy, were a progressive increase in weight and a considerable incidence of hypoglycemia.
When taking insulin, your vision may sometimes be blurry, and it's not because your eyeglasses need cleaning or the aliens are about to beam you up. It's just another potential side effect of insulin, particularly when you first start to take it. The good news is, not only will this resolve fairly quickly, but as your body adjusts, you may end up with better vision than you did before you were diagnosed.
A 2019 Consensus Report from the American Diabetes Association concluded that low-carbohydrate diets (including those that aim for nutritional ketosis) are among the most studied eating patterns for type 2 diabetes” and that these eating patterns, especially very-low-carbohydrate … have been shown to reduce HbA1C glycated hemoglobin and the need for antihyperglycemic medications” ( 22 ). In a pragmatic trial including 262 adults with type 2 diabetes assigned to a very-low-carbohydrate diet, mean weight loss was 11.9 kg and HbA1c decreased by 1.0%, even with substantial reductions in the use of hypoglycemic medications other than metformin ( 23 ). Few clinical trials have examined carbohydrate restriction in type 1 diabetes, possibly due in part to concerns about hypoglycemia and ketoacidosis.